Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agex Therapeutics Inc (NY: AGE )

0.6339 +0.0439 (+7.44%)
Official Closing Price Updated: 8:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,628
Open 0.5800
Bid (Size) 0.6324 (1)
Ask (Size) 0.6850 (7)
Prev. Close 0.5900
Today's Range 0.5800 - 0.6642
52wk Range 0.3720 - 0.8399
Shares Outstanding 37,951,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AgeX Therapeutics Announces Appeal of NYSE American Determination
From AgeX Therapeutics, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final day of the trading week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace

Performance

YTD
+13.40%
+13.40%
1 Month
+9.29%
+9.29%
3 Month
+2.24%
+2.24%
6 Month
+10.24%
+10.24%
1 Year
-18.73%
-18.73%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
AgeX Therapeutics Reports First Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
From AgeX Therapeutics , Inc.
Via Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Via Benzinga
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports First Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
58 Biggest Movers From Yesterday
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
61 Biggest Movers From Yesterday
Via Benzinga
18 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
40 Biggest Movers From Friday
Via Benzinga
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
From AgeX Therapeutics, Inc.
Via Business Wire
Braeden Lichti: The Business of Anti-Aging and Rejuvenation Biotechnology
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
From AgeX Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.